Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer.

Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 04 14; 28(8):1549-1559.

View in: PubMed

subject areas

Androgen Antagonists
Androgen Receptor Antagonists
Benzamides
Humans
Male
Mifepristone
Nitriles
Phenylthiohydantoin
Prospective Studies
Prostate-Specific Antigen
Prostatic Neoplasms, Castration-Resistant
Receptors, Glucocorticoid

authors with profiles

Daniel H. Shevrin
Russell Z. Szmulewitz
Theodore Karrison